Jianqing Lin, MD
Thomas Jefferson University · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianqing Lin, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:54 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT01848067 · Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer · principal investigator
- Ph2NCT01313559 · Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · terminated · Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer · principal investigator
- Ph2NCT01162135 · Digoxin for Recurrent Prostate CancerSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.